{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:04:31Z","timestamp":1762506271266},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":427,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1111\/bjd.12881","type":"journal-article","created":{"date-parts":[[2014,2,7]],"date-time":"2014-02-07T18:40:55Z","timestamp":1391798455000},"page":"162-169","source":"Crossref","is-referenced-by-count":15,"title":["Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea"],"prefix":"10.1093","volume":"171","author":[{"given":"K.","family":"Benkali","sequence":"first","affiliation":[{"name":"Galderma R&D; Sophia Antipolis France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Leoni","sequence":"additional","affiliation":[{"name":"Galderma R&D; Princeton NJ U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Rony","sequence":"additional","affiliation":[{"name":"Galderma R&D; Sophia Antipolis France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Bouer","sequence":"additional","affiliation":[{"name":"Galderma R&D; Sophia Antipolis France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fernando","sequence":"additional","affiliation":[{"name":"Galderma R&D; Princeton NJ U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Graeber","sequence":"additional","affiliation":[{"name":"Galderma R&D; Princeton NJ U.S.A"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Galderma R&D; Sophia Antipolis France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,7,16]]},"reference":[{"issue":"Suppl. 1","key":"10.1111\/bjd.12881-BIB0001|bjd12881-cit-0001","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0039-6257(96)82028-5","article-title":"Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies","volume":"41","author":"Walters","year":"1996","journal-title":"Surv Ophthalmol"},{"key":"10.1111\/bjd.12881-BIB0002|bjd12881-cit-0002","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00061198-199708000-00010","article-title":"Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment","volume":"6","author":"Greenfield","year":"1997","journal-title":"J Glaucoma"},{"key":"10.1111\/bjd.12881-BIB0003|bjd12881-cit-0003","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2133.2011.10716.x","article-title":"Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies","volume":"166","author":"Fowler","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12881-BIB0004|bjd12881-cit-0004","volume-title":"Mirvaso Topical Gel, 0.33%","author":"Galderma Laboratories","year":"2013"},{"key":"10.1111\/bjd.12881-BIB0005|bjd12881-cit-0005","first-page":"650","article-title":"Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies","volume":"12","author":"Fowler","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.12881-BIB0006|bjd12881-cit-0006","volume-title":"ALPHAGAN\u00ae P","author":"Allergan","year":"2011"},{"key":"10.1111\/bjd.12881-BIB0007|bjd12881-cit-0007","unstructured":"US Department of Health and Human Services US Food and Drug Administration Center for Drug Evaluation and Research Acne vulgaris: developing drugs for treatment. Draft guidance http:\/\/www.fda.gov\/downloads\/Drugs\/…\/Guidances\/UCM071292.pdf"},{"key":"10.1111\/bjd.12881-BIB0008|bjd12881-cit-0008","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000211090","article-title":"Principles and criteria in the development and optimization of topical therapeutic products","volume":"6","author":"Shah","year":"1993","journal-title":"Skin Pharmacol"},{"key":"10.1111\/bjd.12881-BIB0009|bjd12881-cit-0009","volume-title":"FDA Drug Approval Package NDA21-262. Alphagan Clinical Pharmacology\/Biopharmaceuticals Review","author":"Allergan","year":"2001"},{"key":"10.1111\/bjd.12881-BIB0010|bjd12881-cit-0010","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2004.03.030","article-title":"Rosacea: I. Etiology, pathogenesis, and subtype classification","volume":"51","author":"Crawford","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12881-BIB0011|bjd12881-cit-0011","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaad.2004.03.033","article-title":"Rosacea: II. Therapy","volume":"51","author":"Pelle","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12881-BIB0012|bjd12881-cit-0012","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1067\/mjd.2002.120625","article-title":"Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea","volume":"46","author":"Wilkin","year":"2002","journal-title":"J Am Acad Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.12881","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.12881\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:08:45Z","timestamp":1676383725000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/171\/1\/162\/6615663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.12881","relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}